1. Home
  2. FEAM vs MREO Comparison

FEAM vs MREO Comparison

Compare FEAM & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 5E Advanced Materials Inc.

FEAM

5E Advanced Materials Inc.

N/A

Current Price

$3.23

Market Cap

56.9M

Sector

Industrials

ML Signal

N/A

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

N/A

Current Price

$0.37

Market Cap

50.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FEAM
MREO
Founded
2016
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.9M
50.3M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
FEAM
MREO
Price
$3.23
$0.37
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
★ $3.75
$1.96
AVG Volume (30 Days)
648.7K
★ 1.6M
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 63.80
16.67
EPS
N/A
★ N/A
Revenue
N/A
★ $500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1,000.00
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.20
52 Week High
$7.50
$2.37

Technical Indicators

Market Signals
Indicator
FEAM
MREO
Relative Strength Index (RSI) 79.33 69.92
Support Level $1.31 $0.28
Resistance Level $4.11 $0.42
Average True Range (ATR) 0.30 0.03
MACD 0.13 0.01
Stochastic Oscillator 95.96 81.65

Price Performance

Historical Comparison
FEAM
MREO

About FEAM 5E Advanced Materials Inc.

5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: